Industry is Exploring How to Empower Pharmacovigilance Programs to Find GMP Root Causes
Dec 17th, 2013
Please Log in to print the full article
Building a system capable of finding quality problems through a firm’s pharmacovigilance program must begin early in development, one of the leading experts in the field, Lilly Global Patient Safety Senior Director John Ayres, is...
You must be a paid subscriber to continue reading this article. If you are a paid subscriber, please Log in. If you are not a paid subscriber, please subscribe now.